Stuka Paul 4/A

What Happened

• Paul Stuka, a director of InspireMD, acquired a total of 75,626 shares of InspireMD common stock in two open-market purchases: 65,626 shares on 2026-05-08 (weighted avg. $1.16; $76,126) and 10,000 shares on 2026-05-11 (weighted avg. $1.19; $11,900). Total consideration for the two purchases was roughly $88,026. These were purchases (insider buys), not sales.

Key Details

• Transaction dates & prices:
  • 2026-05-08: 65,626 shares at $1.16 (weighted avg.; prices ranged $1.15–$1.16) — Footnote F1
  • 2026-05-11: 10,000 shares at $1.19 (weighted avg.; prices ranged $1.17–$1.20) — Footnote F4
• Shares owned after the transaction (per amended filing): directly beneficially owned 632,871 shares (557,245 prior to these purchases + 75,626 acquired); indirectly beneficially owned 423,704 shares through Osiris — Footnotes F2, F3
• Holdings through Osiris: Osiris holds securities reported here; Stuka is managing member of Osiris Partners, LLC and may be deemed to beneficially own those shares but disclaims ownership except as to pecuniary interest — Footnote F5
• Filing/amendment notes: This is an amended Form 4 (filed 2026-05-13) correcting prior reporting (including beneficial ownership details) and to state the trades were NOT made pursuant to a Rule 10b5-1 trading plan (original Form 4 was filed on 2026-05-12 and inadvertently checked the 10b5-1 box) — Footnotes F2, F3, F6. The amendment did not change the economic interest.

Context

• Insider purchases are often watched by investors as a potentially bullish signal because insiders are adding to holdings, but they do not guarantee future stock performance. These were open-market purchases by a company director and not option exercises, gifts, or sales. Information about exact per-trade prices within the reported ranges can be provided by the reporting person upon request (per footnotes).